Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA Communications Hurt By Sequestration As Late-Stage Meetings Begin

Executive Summary

Twenty sponsors now have applications in the new review model, but none have reached the approval decision stage; industry officials say it still is too early to draw conclusions.

Advertisement

Related Content

Sequester, Shutdown Hurt FDA Recruitment, Morale – Hamburg
Sequester, Shutdown Hurt FDA Recruitment, Morale – Hamburg
FDA Recruitment Hurt By Sequester, Shutdown – Hamburg
Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?
Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
PDUFA V: Communications Liaisons Will Help Find Answers, Not Give Them
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
Late-Cycle Approval Predictions Not A Good Idea, FDA Says
Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle
PDUFA V: FDA Application Completeness Crackdown Continues

Topics

Advertisement
UsernamePublicRestriction

Register

PS055251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel